IP Library Granted Patent US 10,479,989
Granted Patent B2
US 10,479,989 · App. 14/898,444 · Granted Nov 19, 2019

Compositions for making random codon-mutant libraries and uses thereof

Inventor: Jesse D. Bloom (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center
C12N15/1031C12N15/102C12N15/67
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,479,989
App. No.
14/898,444
Granted
Nov 19, 2019
Kind
B2
Abstract

The present disclosure relates to compositions and methods for randomly introducing codon-mutations in a target nucleic acid molecule and, more particularly, using wild-type and triplet-randomized oligonucleotides to introduce mutations uniformly across a target nucleotide of interest in a controlled fashion and with a low rate of insertions or deletions.

Claims (22)

1. A method for making a plurality of variant nucleic acid molecules, comprising

(a) amplifying a reference nucleic acid molecule template with a plurality of forward mutagenic oligonucleotides to produce a first plurality of forward mutagenic fragments and separately amplifying the reference nucleic acid molecule template with a plurality of reverse mutagenic oligonucleotides to produce a first plurality of reverse mutagenic fragments, wherein the reference nucleic acid molecule template comprises a plurality of codons that encode a reference polypeptide and wherein each of the plurality of forward and reverse mutagenic oligonucleotides comprise a codon randomized at one to three nucleotides and the oligonucleotides comprise from nine to 100 nucleotides, and wherein the randomized codons correspond to all codons of the reference nucleic acid molecule template except the initiation codon;

(b) purifying the first plurality of forward and reverse mutagenic fragments and mixing the purified first plurality of forward and reverse mutagenic fragments to produce a first mixed mutagenic nucleic acid molecule fragment template composition; and

(c) joining the mixed nucleic acid molecule fragments of the first mixed mutagenic nucleic acid molecule fragment template composition by amplifying in a single reaction with the plurality of forward and reverse mutagenic oligonucleotides from step (a) to produce a first plurality of joined mutagenic nucleic acid molecules;

thereby introducing codon variants at random locations at a controlled mutation rate across the length of the reference nucleic acid molecule template.

2. The method according to claim 1 , wherein the method further comprises purifying the first plurality of joined mutagenic nucleic acid molecules and repeating steps (a) through steps (c) of claim 1 to produce a second plurality of joined mutagenic nucleic acid molecules.

3. The method according to claim 2 , wherein the method further comprises purifying the second plurality of joined mutagenic nucleic acid molecules and repeating steps (a) through steps (c) of claim 1 to produce a third plurality of joined mutagenic nucleic acid molecules.

4. The method according to claim 3 , wherein the method further comprises repeating steps (a) through steps (c) of claim 1 at least 3, 4, 5, 6, 7, 8, 9, 10 or more times by purifying the plurality of joined mutagenic nucleic acid molecules generated in the previous round of the method and performing steps (a) through steps (c).

5. The method according to claim 1 , further comprising the step of amplifying the reference nucleic acid molecule template before step (a) of claim 1 with an oligonucleotide complimentary to the 5′-end of the reference nucleic acid molecule template and with an oligonucleotide complimentary to the 3′-end of the reference nucleic acid molecule template, wherein the 5′-end and 3′-end oligonucleotides comprise a sequence recognized by a restriction endonuclease to produce an end-modified reference nucleic acid molecule template; and purifying the end-modified reference nucleic acid molecule template.

6. The method according to claim 1 , wherein the randomized codon of the forward and reverse mutagenic oligonucleotides is NNN, YTN, NTN, NNW, NNS, NNM, NNK, NNR, NNB, NND, NNV, NNH, BBB, DDD, VVV, HHH, NNA, NNT, NNC, NNG, NAN, NCN, NGN, ANN, TNN, CNN, GNN or any combination thereof.

7. The method according to claim 1 , wherein the randomized codon of the forward and reverse mutagenic oligonucleotides is located in the middle of the oligonucleotide, near the 5′-end of the oligonucleotide, near the 3′-end of the oligonucleotide, or any combination thereof.

8. The method according to claim 1 , wherein the forward mutagenic oligonucleotide, reverse mutagenic oligonucleotide, or both individually comprise from about 20 to about 50 nucleotides.

9. The method according to claim 1 , wherein the codon variants at random locations across the length of the reference nucleic acid molecule template comprise a number of mutations and the number of mutations per reference nucleic acid molecule template follows an approximate Poisson distribution.

10. The method according to claim 1 , wherein the codon variants at random locations across the length of the reference nucleic acid molecule template comprise mutations that occur uniformly along the length of the reference nucleic acid molecule template.

11. The method according to claim 1 , wherein the codon variants at random locations across the length of the reference nucleic acid molecule template comprise a uniform base composition.

12. The method according to claim 1 , wherein the reference nucleic acid molecule templates comprises multiple mutations that are not clustered.

13. The method according claim 1 , wherein the number of codon variants introduced comprises from about one to about ten different mutants.

14. The method according to claim 1 , wherein the method results in no more than 0.5 insertions, deletions, or a combination thereof per reference nucleic acid molecule.

15. The method according to claim 1 , wherein the reference nucleic acid molecule is an animal, viral, bacterial, fungal, plant, protist, or archaebacterial gene.

16. The method according to claim 15 , wherein the viral gene is an influenza gene.

17. The method according to claim 16 , wherein the influenza gene is a nucleoprotein or hemagglutinin gene.

18. The method according to claim 1 , wherein the forward mutagenic oligonucleotide, reverse mutagenic oligonucleotide, or both individually comprise non-coding sequence from the reference nucleic acid molecule template.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Aug 4, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060722/0441 →
MERGER AND CHANGE OF NAME Recorded Jun 9, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060329/0793 →
CONFIRMATORY LICENSE Recorded Jan 25, 2017
From: FRED HUTCHINSON CANCER RESEARCH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041480/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: BLOOM, JESSE D.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 037297/0940 →
Continuity (2)
Provisional Application 61835377 · Jun 14, 2013
Related Publication 20160145603A1 · May 26, 2016